{{Rsnum
|rsid=2409191
|Chromosome=21
|position=26736504
|Orientation=plus
|GMAF=0.2264
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 17.7 | 82.3
| HCB | 27.0 | 51.1 | 21.9
| JPT | 34.5 | 52.2 | 13.3
| YRI | 0.7 | 17.7 | 81.6
| ASW | 0.0 | 15.8 | 84.2
| CHB | 27.0 | 51.1 | 21.9
| CHD | 19.3 | 57.8 | 22.9
| GIH | 2.0 | 25.7 | 72.3
| LWK | 0.0 | 24.5 | 75.5
| MEX | 1.7 | 32.8 | 65.5
| MKK | 0.6 | 27.6 | 71.8
| TSI | 1.0 | 10.8 | 88.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2409191
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.11, combined P value= 9.29E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470182
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2409191
|overall_frequency_n=105
|overall_frequency_d=128
|overall_frequency=0.820312
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=89
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}